UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 183

Sortiert nach

Second-line nivolumab in relapsed small-cell lung cancer: CheckMate 331

Annals of oncology, 2021-05, Vol.32 (5), p.631-641

2021

Volltextzugriff (PDF)

Nivolumab (nivo) plus ipilimumab (ipi), nivo, or placebo (pbo) as maintenance therapy in patients (pts) with extensive disease small cell lung cancer (ED-SCLC) after first-line (1L) platinum-based chemotherapy (chemo): Results from the double-blind, randomized phase III CheckMate 451 study

Annals of oncology, 2019-04, Vol.30, p.ii77-ii77

2019

Volltextzugriff (PDF)

Thalidomide Radiosensitizes Tumors through Early Changes in the Tumor Microenvironment

Clinical cancer research, 2005-01, Vol.11 (2), p.743-750

2005

Volltextzugriff (PDF)

Efficacy and safety of nivolumab (nivo) monotherapy versus chemotherapy (chemo) in recurrent small cell lung cancer (SCLC): Results from CheckMate 331

Annals of oncology, 2018-12, Vol.29, p.x43-x43

2018

Volltextzugriff (PDF)

Cluster analysis of BOLD fMRI time series in tumors to study the heterogeneity of hemodynamic response to treatment

Magnetic resonance in medicine, 2003-06, Vol.49 (6), p.985-990

2003

Volltextzugriff (PDF)

Phase II Study of Nivolumab (anti-PD-1, BMS-936558, ONO-4538) in Patients with Advanced, Refractory Squamous Non-Small Cell Lung Cancer

International journal of radiation oncology, biology, physics, 2014-12, Vol.90 (5), p.1266-1267

2014

Volltextzugriff (PDF)

How does blood oxygen level-dependent (BOLD) contrast correlate with oxygen partial pressure (pO2) inside tumors?

Magnetic resonance in medicine, 2002-12, Vol.48 (6), p.980-986

2002

Volltextzugriff (PDF)

583 TUMOR RESPONSE IN A PHASE 2 STUDY OF FIRST-LINE BRIVANIB IN HEPATOCELLULAR CARCINOMA (HCC): COMPARISON OF MODIFIED WHO AND MODIFIED RECIST CRITERIA

Journal of hepatology, 2010, Vol.52, p.S230-S231

2010

Volltextzugriff (PDF)

68P Evaluation of flat dosing for nivolumab (NIVO) + ipilimumab (IPI) in first-line (1L) unresectable malignant pleural mesothelioma (MPM): CheckMate 743 (CM 743)

Annals of oncology, 2020-12, Vol.31, p.S1445-S1445

2020

Volltextzugriff (PDF)

P.3.c.075 A 46-week evaluation of aripiprazole in combination with lithium/valproate in bipolar mania (CN138–134)

European neuropsychopharmacology, 2008, Vol.18, p.S447-S447

2008

Volltextzugriff (PDF)

PW01-36 - The long-term safety, tolerability and effectiveness of adjunctive aripiprazole to lithium/valproate in bipolar I patients partially non-responsive to mood stabilisers

European psychiatry, 2010, Vol.25 (S1), p.1455-1455, Article 25-E1438

2010

Volltextzugriff (PDF)

Assessment of tumor oxygenation by electron paramagnetic resonance: principles and applications

NMR in biomedicine, 2004-08, Vol.17 (5), p.240-262

2004

Volltextzugriff (PDF)

749P Nivolumab (N) alone or in combination with ipilimumab (I) in patients (pts) with platinum-pretreated metastatic urothelial carcinoma (mUC): Extended follow-up from CheckMate 032

Annals of oncology, 2020-09, Vol.31, p.S582-S583

2020

Volltextzugriff (PDF)

ID:2908 First-Line Nivolumab + Ipilimumab vs Chemotherapy in Unresectable Malignant Pleural Mesothelioma: CheckMate 743

Journal of thoracic oncology, 2020-10, Vol.15 (10), p.e42-e42

2020

Volltextzugriff (PDF)

Effect of anesthesia on the signal intensity in tumors using BOLD-MRI: Comparison with flow measurements by Laser Doppler flowmetry and oxygen measurements by luminescence-based probes

Magnetic resonance imaging, 2004-09, Vol.22 (7), p.905-912

2004

Volltextzugriff (PDF)

A randomized, open-label, phase 3 study of nivolumab in combination with ipilimumab vs extreme regimen (cetuximab + cisplatin/carboplatin + fluorouracil) as first-line therapy in patients with recurrent or metastatic squamous cell carcinoma of the head and neck-CheckMate 651

Annals of oncology, 2016-10, Vol.27, p.vi350-vi350

2016

Volltextzugriff (PDF)

LBA1_PRNivolumab (nivo) plus ipilimumab (ipi), nivo, or placebo (pbo) as maintenance therapy in patients (pts) with extensive disease small cell lung cancer (ED-SCLC) after first-line (1L) platinum-based chemotherapy (chemo): Results from the double-blind, randomized phase III CheckMate 451 study

Annals of oncology, 2019-04, Vol.30 (Supplement_2)

2019

Volltextzugriff (PDF)

LBA5Efficacy and safety of nivolumab (nivo) monotherapy versus chemotherapy (chemo) in recurrent small cell lung cancer (SCLC): Results from CheckMate 331

Annals of oncology, 2018-12, Vol.29 (suppl_10)

2018

Volltextzugriff (PDF)

Early reoxygenation in tumors after irradiation: Determining factors and consequences for radiotherapy regimens using daily multiple fractions

International journal of radiation oncology, biology, physics, 2005-11, Vol.63 (3), p.901-910

2005

Volltextzugriff (PDF)

Physiological noise in murine solid tumours using T2-weighted gradient-echo imaging: a marker of tumour acute hypoxia?

Physics in medicine & biology, 2004-08, Vol.49 (15), p.3389-3411

2004

Volltextzugriff (PDF)

Botulinum toxin potentiates cancer radiotherapy and chemotherapy

Clinical cancer research, 2006-02, Vol.12 (4), p.1276-1283

2006

Volltextzugriff (PDF)

Phase II Study of Nivolumab (anti-PD-1, BMS-936558, ONO-4538) in Patients with Advanced, Refractory Squamous Non-Small Cell Lung Cancer: Metastatic Non-small Cell Lung Cancer

International journal of radiation oncology, biology, physics, 2014-12, Vol.90 (5), p.1266-1267

2014

Volltextzugriff (PDF)

Brivanib (B) in Advanced Ovarian Cancer (OC): Subset Results of a Phase 2 Randomized Discontinuation Trial (RDT)

Annals of oncology, 2012-09, Vol.23, p.ix319

2012

Volltextzugriff (PDF)

Optimal assessment of treatment benefit with targeted agents for hepatocellular carcinoma (HCC): An analysis of brivanib phase II data

Journal of clinical oncology, 2010-05, Vol.28 (15_suppl), p.4096-4096

2010

Volltextzugriff (PDF)

Changes in tumor oxygenation/perfusion induced by the no donor, isosorbide dinitrate, in comparison with carbogen: monitoring by EPR and MRI

International journal of radiation oncology, biology, physics, 2000-09, Vol.48 (2), p.565-570

2000

Volltextzugriff (PDF)

1 – 25 von 183

Suche als RSS-Feed

Aktive Filter

ThemaMagnetic Properties And Materials

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(145)
Mit Volltextzugriff
(175)

Publikationsform

Sprache

Erscheinungsjahr

n.n

Thema

Science & Technology
(88)
Physics
(57)
Physical Sciences
(56)
Technology
(46)
Materials Science
(36)
Materials Science, Multidisciplinary
(32)
Physics, Applied
(26)
Physics, Condensed Matter
(24)
Life Sciences & Biomedicine
(23)
Animals
(19)
Exact Sciences And Technology
(19)
Male
(17)
Condensed Matter
(15)
Mice
(15)
Applied Sciences
(14)
Metals. Metallurgy
(14)
Chemistry
(13)
Biological And Medical Sciences
(12)
Radiology, Nuclear Medicine & Medical Imaging
(12)
Chemistry, Physical
(11)

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

Second-line nivolumab in relapsed small-cell lung cancer: CheckMate 331

Nivolumab (nivo) plus ipilimumab (ipi), nivo, or placebo (pbo) as maintenance therapy in patients (pts) with extensive disease small cell lung cancer (ED-SCLC) after first-line (1L) platinum-based chemotherapy (chemo): Results from the double-blind, randomized phase III CheckMate 451 study

Thalidomide Radiosensitizes Tumors through Early Changes in the Tumor Microenvironment

Efficacy and safety of nivolumab (nivo) monotherapy versus chemotherapy (chemo) in recurrent small cell lung cancer (SCLC): Results from CheckMate 331

Cluster analysis of BOLD fMRI time series in tumors to study the heterogeneity of hemodynamic response to treatment

Phase II Study of Nivolumab (anti-PD-1, BMS-936558, ONO-4538) in Patients with Advanced, Refractory Squamous Non-Small Cell Lung Cancer

How does blood oxygen level-dependent (BOLD) contrast correlate with oxygen partial pressure (pO2) inside tumors?

583 TUMOR RESPONSE IN A PHASE 2 STUDY OF FIRST-LINE BRIVANIB IN HEPATOCELLULAR CARCINOMA (HCC): COMPARISON OF MODIFIED WHO AND MODIFIED RECIST CRITERIA

68P Evaluation of flat dosing for nivolumab (NIVO) + ipilimumab (IPI) in first-line (1L) unresectable malignant pleural mesothelioma (MPM): CheckMate 743 (CM 743)

P.3.c.075 A 46-week evaluation of aripiprazole in combination with lithium/valproate in bipolar mania (CN138–134)

PW01-36 - The long-term safety, tolerability and effectiveness of adjunctive aripiprazole to lithium/valproate in bipolar I patients partially non-responsive to mood stabilisers

Assessment of tumor oxygenation by electron paramagnetic resonance: principles and applications

749P Nivolumab (N) alone or in combination with ipilimumab (I) in patients (pts) with platinum-pretreated metastatic urothelial carcinoma (mUC): Extended follow-up from CheckMate 032

ID:2908 First-Line Nivolumab + Ipilimumab vs Chemotherapy in Unresectable Malignant Pleural Mesothelioma: CheckMate 743

Effect of anesthesia on the signal intensity in tumors using BOLD-MRI: Comparison with flow measurements by Laser Doppler flowmetry and oxygen measurements by luminescence-based probes

A randomized, open-label, phase 3 study of nivolumab in combination with ipilimumab vs extreme regimen (cetuximab + cisplatin/carboplatin + fluorouracil) as first-line therapy in patients with recurrent or metastatic squamous cell carcinoma of the head and neck-CheckMate 651

LBA1_PRNivolumab (nivo) plus ipilimumab (ipi), nivo, or placebo (pbo) as maintenance therapy in patients (pts) with extensive disease small cell lung cancer (ED-SCLC) after first-line (1L) platinum-based chemotherapy (chemo): Results from the double-blind, randomized phase III CheckMate 451 study

LBA5Efficacy and safety of nivolumab (nivo) monotherapy versus chemotherapy (chemo) in recurrent small cell lung cancer (SCLC): Results from CheckMate 331

Early reoxygenation in tumors after irradiation: Determining factors and consequences for radiotherapy regimens using daily multiple fractions

Physiological noise in murine solid tumours using T2-weighted gradient-echo imaging: a marker of tumour acute hypoxia?

Botulinum toxin potentiates cancer radiotherapy and chemotherapy

Phase II Study of Nivolumab (anti-PD-1, BMS-936558, ONO-4538) in Patients with Advanced, Refractory Squamous Non-Small Cell Lung Cancer: Metastatic Non-small Cell Lung Cancer

Brivanib (B) in Advanced Ovarian Cancer (OC): Subset Results of a Phase 2 Randomized Discontinuation Trial (RDT)

Optimal assessment of treatment benefit with targeted agents for hepatocellular carcinoma (HCC): An analysis of brivanib phase II data

Changes in tumor oxygenation/perfusion induced by the no donor, isosorbide dinitrate, in comparison with carbogen: monitoring by EPR and MRI

Aktive Filter

Suchergebnisse filtern